As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > REGULATORY
REGULATORY
- MHLW Calls for Package Insert Revisions for 6 Products Including Strattera
October 28, 2011
- US FDA Extends Action Date for SGLT-2 Inhibitor Dapagliflozin
October 28, 2011
- Mr Yoshimura of Astem to Be Named as Successor of Mr Matsutani: CSIMC Expert Member
October 28, 2011
- Drug-induced Hepatitis Victims Petition Against Creation of Korosho-Proposed “Third-Party Organization”
October 28, 2011
- Korosho Study Group Surveying Drug Makers’ Regulatory Compliance Systems
October 28, 2011
- Medical Benefits Rose 4.2% in FY2009, Breaking ¥30 Tril. for 1st Time
October 28, 2011
- MHLW Releases Safety Information, Calling for Proper Use of Champix
October 27, 2011
- Subcommittee to Recommend Use of Most-recent 3-Year Averages in Drug Cost Calculation
October 27, 2011
- Planning to Resume “Public-Private Dialog” by Year-End: EAD Director Kamata
October 27, 2011
- DPJ Lawmakers Opposed to TPP Criticize MHLW at Hearings
October 27, 2011
- DPJ Lawmakers Opposed to TPP Criticize Korosho at Hearings
October 26, 2011
- New Rules for Application of GCP Ordinance to Take Effect April 1, 2012
October 26, 2011
- Supreme Court Upholds Ban on Reimbursement in “Mixed Healthcare”
October 26, 2011
- US FDA Approves 1st Generic Versions of Zyprexa, Eli Lilly’s Top Mainstay Product
October 26, 2011
- Subcommittee to Recommend Use of Most-recent 3-year Averages in Drug Cost Calculation
October 26, 2011
- Chuikyo Subcommittee Approves Revision of Foreign Price Adjustment Rule
October 26, 2011
- Korosho to Take Stricter Look at Companies’ Market Size Forecasts
October 26, 2011
- JMA, JPA Oppose Increase in Patients’ Copayments for OTC-like Drugs
October 26, 2011
- TPP Could Have Major Impact on NHI Price System: Ms Weatherall of University of Queensland
October 26, 2011
- Patent Office to Revise Rules for Granting Patent Extensions
October 25, 2011
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…